-

05:34:14 PM

IXHL Stock News

IXHL - Incannex Healthcare Limited

03/16/23 8:51 AM

Nasdaq : IXHL

partnership

Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts

Highlights: Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas. First clinic will open in Melbourne in 2023, followed by rapid expansion based on development of sound operating model. Dr. Paul Liknaitzky, Professor Suresh Sundram and Sean O’Carroll

RHEA-AI

very positive

03/15/23 7:30 AM

Nasdaq : IXHL

clinical trial

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit for the psilocybin treatment arm versus the placebo treatment arm at the conclusion of the study period.

RHEA-AI

neutral

03/03/23 7:30 AM

Nasdaq : IXHL

clinical trial

Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Highlights: Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own psilocybin drug product. The psilocybin is designed for use in Incannex’s ongoing psilocybin-assisted psychotherapy “PsiGAD” clinical development program for generalised anxiety disorder and for

RHEA-AI

neutral

02/28/23 7:25 AM

Nasdaq : IXHL

clinical trial

Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Highlights: Incannex has commenced a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis. The Phase 2 trial follows a successful Phase 1 trial, where IHL-675A was observed to be well tolerated,

RHEA-AI

neutral

01/18/23 8:00 AM

Nasdaq : IXHL

clinical trial

Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to

RHEA-AI

positive

12/06/22 8:00 AM

Nasdaq : IXHL

Incannex Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to

RHEA-AI

neutral

11/29/22 8:00 AM

Nasdaq : IXHL

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it

RHEA-AI

very positive

11/28/22 8:00 AM

Nasdaq : IXHL

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it

RHEA-AI

neutral

11/17/22 8:00 AM

Nasdaq : IXHL

Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’)

Highlights: Incannex has engaged CMAX Clinical Research and Novotech CRO to undertake a bioavailability/bioequivalence (‘BA/BE’) study to assess the pharmacokinetics and tolerability of IHL-42X in 116 participants Incannex is well progressed in drafting an Investigational New Drug (‘IND’)

RHEA-AI

neutral

10/28/22 8:00 AM

Nasdaq : IXHL

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 September

RHEA-AI

positive